Company: Amunix Pharmaceuticals Inc.
Job title: President & Chief Technology Officer
HER2 remains one of the most validated and established oncology drug targets to date. However, a huge unmet need remains amongst patients with HER2 expressing cancers. Three recent HER2-targeted drug approvals for breast cancer, as well as exciting data from ongoing clinical trials investigating novel HER2-targeted therapies in gastric, lung, ovarian, endometrial, colon cancer, and beyond, are stimulating a new era of HER2-targeted drug development. This is being met with refreshed excitement, enthusiasm, and R&D investment for the HER2 target.
Tuesday, November 2 – Pre-Conference Workshop